NOVARTIND

Evonile Pharma Ltd.

BSE: 500672

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,824.50+137.8 (+8.17%)

23 Oct, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

78.6 / 100

Value Score

23.2 / 100

Price Momentum Score

88.3 / 100

QVM Score

76.5 / 100

Key Metrics

Market Cap

4504.87

P/E (TTM)

46.08

P/B

5.51

P/S (TTM)

12.16

EV/EBITDA

37.73

CAPE (5Y)

55.64

ROE (TTM)

11.63

ROCE (TTM)

11.44

ROA (TTM)

9.68

Avg 3Y ROE

12.01

Earnings 3Y CAGR

11.15

Sales 3Y CAGR

2.08

Sales 5Y CAGR

-0.86

Debt/Equity

0.00

Consensus TP

Strong Buy %

Promoter Holding

70.68

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Evonile Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 88.3 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

88.3 / 100

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 46.08 indicates that the stock is expensive on a standalone basis and is at a 51.23% premium to industry median P/E

What is P/E Ratio?

Median: 30.47

Value 46.08

-0.82614.73

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 52.4 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

52.4 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Evonile Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Evonile Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Evonile Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Total Promoter	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68
Indian Promoter	-	-	-	-	70.68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.23
Foreign Promoter	70.68	70.68	70.68	70.68	-	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	70.68	56.45
Institutions	0.86	0.86	0.87	0.84	0.84	0.90	0.81	0.87	0.89	0.92	0.94	0.94	0.94	0.99	0.84	0.71	0.71	0.71	0.71	0.71	0.71	0.71	0.71	0.82	0.69	1.51	2.71
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.69	0.77
FI/Bank/Insurance	0.82	0.82	0.82	0.78	0.78	0.77	0.77	0.77	0.77	0.77	0.77	0.77	0.77	0.75	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.12
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.04	0.04	0.05	0.05	0.06	0.06	0.03	0.09	0.12	0.14	0.17	0.17	0.17	0.23	0.32	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.17	0.16	1.21
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.13	0.60
Non-Institution	28.46	28.46	28.45	28.48	28.48	28.43	28.51	28.46	28.43	28.41	28.38	28.38	28.38	28.33	28.48	28.61	28.61	28.61	28.61	28.61	28.61	28.61	28.61	28.51	28.63	27.81	26.61
Bodies Corporate	2.89	2.71	2.39	2.32	2.33	2.35	2.26	2.31	2.31	2.30	2.62	2.59	2.22	2.20	2.14	2.30	2.47	2.25	2.26	2.28	2.13	2.25	2.21	2.19	2.08	2.02	2.38
Others (incl. Retail) No. of shareholders	25.57 40,735	25.75 41,597	26.06 40,692	26.16 41,111	26.15 41,256	26.08 43,457	26.25 44,829	26.15 44,326	26.12 44,070	26.11 43,696	25.76 42,959	25.79 42,312	26.16 41,657	26.13 43,056	26.34 43,696	26.31 42,828	26.14 40,943	26.36 38,979	26.35 39,315	26.33 38,647	26.48 38,866	26.36 38,762	26.40 39,092	26.32 39,210	26.55 37,872	25.79 36,277	24.23 37,862

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Evonile Pharma Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
NOVARTIS AG Promoter	July-2026	Off Market (Disposal) 30th Jul 2026	70.68 %	₹ 789.02	1.75 cr	₹ 1376.89 cr

Corporate Actions

History of Evonile Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 25/share
Record date: 23rd Jul 2025Ex-date: 23rd Jul 2025
Announced on: 9th May 2025
Dividend₹ 25/share
Record date: 23rd Jul 2024Ex-date: 23rd Jul 2024
Announced on: 10th May 2024
Dividend₹ 10/share
Record date: 20th Jul 2023Ex-date: 20th Jul 2023
Announced on: 10th May 2023
Dividend₹ 37.50/share
Record date: 20th Jul 2023Ex-date: 20th Jul 2023
Announced on: 10th May 2023
Dividend₹ 10/share
Record date: 21st Jul 2022Ex-date: 20th Jul 2022
Announced on: 19th May 2022

Company Profile

Overview of Evonile Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Novartis India Limited is an India-based pure-play medicines company. The Company is focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging plat...

Key personnel

Ms. Chandni Maru

Chief Compliance Officer, Company Secretary

Mr. Ashok BhatiaD

Additional Non-Executive Non-Independent Director

Dr. Jagriti GuptaD

Additional Non-Executive Non-Independent Director

Mr. Kshitij ShethD

Additional Non-Executive Non-Independent Director

Mr. Ramesh RamaduraiD

Additional Independent Director

Ms. Suchita SharmaD

Additional Independent Director

Mr. Shashank SinhaD

Additional Independent Director

Ms. Gira SardesaiD

Additional Non-Executive Independent Director

Incorporated on

13 Dec 1947

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

01 Jan 1990

Free Float

66,90,731

Website

Phone no.

+912224958400

Address

Inspire Bkc, Part Of 601 And 701, Bandra Kurla Complex, Bandra East, MUMBAI, 400051, India

Frequently Asked Questions

What is the current share price of Evonile Pharma Ltd.?

The current share price of Evonile Pharma Ltd. is ₹ 1,824.50 as of 23 Oct 2026.

What is the market capitalisation of Evonile Pharma Ltd.?

The market capitalisation of Evonile Pharma Ltd. stands at ₹ 4,504.87 Cr.

What is the PE ratio of Evonile Pharma Ltd.?

The Price-to-Earnings (PE) ratio of Evonile Pharma Ltd. is 46.08 as of the latest trailing twelve months data.

What is the ROE and ROCE of Evonile Pharma Ltd.?

Evonile Pharma Ltd. has a Return on Equity (ROE) of 11.63% and a Return on Capital Employed (ROCE) of 11.44% as per the latest financial reports.

What is the 52-week high and low of Evonile Pharma Ltd.?

The 52-week high of Evonile Pharma Ltd. is - and the 52-week low is -.

What is the dividend yield of Evonile Pharma Ltd.?

The dividend yield of Evonile Pharma Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Evonile Pharma Ltd.?

Foreign Institutional Investors (FII) hold 1.21%, Domestic Institutional Investors (DII) hold 0.89% and retail/public investors hold 24.23% of Evonile Pharma Ltd. shares.

What sector does Evonile Pharma Ltd. belong to?

Evonile Pharma Ltd. operates in the Healthcare sector.

What is the beta of Evonile Pharma Ltd.?

The beta of Evonile Pharma Ltd. is 0.14, indicating its price volatility relative to the broader market. Over the past 1 year, Evonile Pharma Ltd. has delivered an absolute return of 111.89%.

What is the RSI of Evonile Pharma Ltd.?

The 14-day Relative Strength Index (RSI) of Evonile Pharma Ltd. is 45.14, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Evonile Pharma Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Evonile Pharma Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions